Format
Sort by

Send to

Choose Destination

Search results

Items: 13

1.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*..

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876.

2.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators..

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814.

3.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators., Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624.

4.

Production of deuterated zeaxanthin by Flavobacterium multivorum and its detection by resonance Raman and mass spectrometric methods.

Bhosale P, Teredesai PV, Lihong J, Ermakov IV, Gellermann W, Bernstein PS.

Biotechnol Lett. 2005 Nov;27(21):1719-23.

PMID:
16247681
5.

A Raman study of CdSe and ZnSe nanostructures.

Teredesai PV, Deepak FL, Govindaraj A, Sood AK, Rao CN.

J Nanosci Nanotechnol. 2002 Oct;2(5):495-8.

PMID:
12908286
6.

"U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc.

Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P.

Kidney Int. 1998 Aug;54(2):561-9. Erratum in: Kidney Int 1998 Oct;54(4):1417.

7.

Investigations into the mechanism of the phosphaturia induced by chlorothiazide.

Winaver J, Teredesai P, Anast C, Puschett JB.

J Pharmacol Exp Ther. 1981 Jul;218(1):46-54. No abstract available.

PMID:
7241388
8.

Mechanism of the phosphaturia due to chlorothiazide.

Puschett JB, Winaver J, Teredesai P.

Adv Exp Med Biol. 1980;128:155-7.

PMID:
7424671
9.

Therapy of renal osteodystrophy with dihydrotachysterol in non-dialyzed patients.

Teredesai P, Winaver J, Martin LG, Cranley R, Conner TB, Hartsock RJ, Puschett JB.

Clin Nephrol. 1980 Jan;13(1):31-9.

PMID:
7363513
10.

Dissociative effects of piretanide on proximal tubular PO4 and HCO3 transport.

Winaver J, Sylk DB, Teredesai PR, Robertson JS, Puschett JB.

Am J Physiol. 1980 Jan;238(1):F60-8.

PMID:
7356023
11.

Diabetic nephropathy as the mode of presentation of diabetes mellitus.

Winaver J, Teredesai P, Feldman HA, Stachura I, Cavallo T, Puschett JB.

Metabolism. 1979 Oct;28(10):1023-30.

PMID:
491959
12.

Acute effects of piretanide in normal subjects.

Teredesai P, Puschett JB.

Clin Pharmacol Ther. 1979 Mar;25(3):331-9.

PMID:
32985
13.

Uncoupling of proximal sodium bicarbonate from sodium phosphate transport by bumetanide.

Puschett JB, Sylk D, Teredesai PR.

Am J Physiol. 1978 Nov;235(5):F403-8.

PMID:
727259
Items per page

Supplemental Content

Loading ...
Support Center